Overview
Swedish medical technology firm's Q3 sales fell 10% in SEK, rose 2% in constant currency
Adjusted gross margin improved to 38.3% due to product launches and pricing
Company incurred SEK 417 mln restructuring charge, expects annual savings over SEK 500 mln
Outlook
Elekta expects full-year 2025/26 net sales to grow in constant currency
Company anticipates continuous negative impact on earnings from FX and tariffs
Result Drivers
SALES GROWTH IN CONSTANT CURRENCY - Net sales increased by 2% in constant exchange rates, driven by Europe and China
RESTRUCTURING CHARGE - SEK 417 mln restructuring charge related to change of operating model, expected to reduce cost base by more than SEK 500 mln annually
GROSS MARGIN IMPROVEMENT - Adjusted gross margin rose to 38.3% due to product launches and improved pricing, despite negative impacts from tariffs and currency changes
Company press release: ID:nMFN1hM857
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Sales
SEK 4.24 bln
Q3 Adjusted EPS
SEK 0.88
Q3 Gross Margin
35.1%
Q3 Adjusted EBIT
SEK 504 mln
Q3 Adjusted EBIT Margin
11.9%
Q3 Adjusted Gross Margin
38.3%
Q3 EBIT
SEK 87 mln
Q3 EBIT Margin
2.0%
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 5 "strong buy" or "buy", 5 "hold" and 6 "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."
Wall Street's median 12-month price target for Elekta AB (publ) is SEK53.00, about 7.7% below its March 4 closing price of SEK57.45
The stock recently traded at 15 times the next 12-month earnings vs. a P/E of 15 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)